---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-24-000010"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:21:00.251018+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics FY2023 net loss $20.3M; $51M PIPE funds Phase 3 cadisegliatin trial

## Summary
- Net loss attributable to shareholders $20.3M ($9.71/share) in FY2023 vs $19.2M ($9.98) in FY2022.
- Cash $9.4M at Dec 31, 2023; subsequent $51M PIPE from institutional investors and JDRF T1D Fund closed Feb 28, 2024.
- First Phase 3 trial of cadisegliatin for type 1 diabetes to enroll first patient in Q2 2024; top-line data expected by Q1 2026.
- R&D expenses $13.6M in FY2023 (up 10% YoY); G&A expenses $11.9M (down 2% YoY).
- Board reduced from 9 to 7; three new directors designated by new investors including Srinivas Akkaraju from Samsara.

## SEC filing metadata
- accession: 0001641489-24-000010
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000010/0001641489-24-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000010/vtvt-20240313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-24-000010
- JSON: https://secwatch.observer/filing/0001641489-24-000010.json
- Plain text: https://secwatch.observer/filing/0001641489-24-000010.txt

## Key facts
- Earnings Releases
  vTv Therapeutics Inc. reported financial results for the fiscal year ended December 31, 2023.
  - Period: the fiscal year ended December 31, 2023
  - Result: reported results
  source text: On March 13, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000010/0001641489-24-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.